Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Repligen Corporation Common Stock — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.59 (market cap $1.04B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 10.7× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Repligen Corporation Common Stock for 0 Days on average.
| GSG | RGEN | |
|---|---|---|
Market Cap | $1.04B | $11.14B |
Volume | 1,727,795 | 1,259,263 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $194.57 |
52-Week Low | $22.48 | $102.87 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.77, up 0.96% with strong bullish technical signals from moving averages. The ETF shows volatile fundamentals with 2024 revenue of $51.25M and net income of $69.99M, though historical trends reveal significant profit margin swings from -126.61% in 2023 to 136.56% in 2024. Recent media coverage highlights commodity-focused positioning with energy exposure driving performance.
Outlook remains cautiously optimistic given bullish technical indicators and commodity market strength, but investors face volatility risks from energy sector exposure and geopolitical factors. The ETF's performance is heavily tied to broader commodity cycles, requiring careful monitoring of energy markets and global economic conditions.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
